Global Sacral Neuromodulation System Market Research Report 2024(Status and Outlook)
The global Sacral Neuromodulation System market size was valued at US$ 812.6 million in 2024 and is projected to reach US$ 1.37 billion by 2030, at a CAGR of 9.1% during the forecast period 2024-2030.
The United States Sacral Neuromodulation System market size was valued at US$ 365.4 million in 2024 and is projected to reach US$ 587.2 million by 2030, at a CAGR of 8.2% during the forecast period 2024-2030.
Sacral Neuromodulation Systems are implantable medical devices used to treat bladder and bowel dysfunction by delivering mild electrical pulses to the sacral nerves, modulating neural activity and improving pelvic floor function.
The global Sacral Neuromodulation System market is experiencing rapid growth, driven by increasing prevalence of overactive bladder, fecal incontinence, and non-obstructive urinary retention, as well as growing awareness and acceptance of neuromodulation therapies. In 2023, global implantations of sacral neuromodulation devices reached approximately 55,000 units, with North America accounting for 55% of procedures. Urinary incontinence remains the largest indication, representing 65% of implantations, followed by fecal incontinence at 25%. The market saw a significant boost from expanded insurance coverage and reimbursement policies, leading to a 18% increase in procedure volumes in 2023. Technological advancements have focused on improving device longevity, MRI compatibility, and patient comfort, with new systems offering up to 15 years of battery life and full-body MRI compatibility. The market is witnessing strong growth in rechargeable devices, increasing at 15% annually, driven by their longer lifespan and reduced need for replacement surgeries. In 2023, new guidelines from urological associations led to a 25% increase in the adoption of sacral neuromodulation as a second-line therapy for refractory overactive bladder. The industry faces challenges from competition with pharmaceutical treatments and other neuromodulation approaches, but the long-term efficacy and cost-effectiveness of sacral neuromodulation continue to drive adoption. Emerging applications in chronic pelvic pain are showing promise, with clinical trials for this indication growing at 20% CAGR, albeit from a small base. Looking ahead, the market is expected to benefit from innovations in closed-loop stimulation systems and personalized therapy algorithms, with next-generation sacral neuromodulation devices projected to grow at 12% CAGR through 2030.
Report Overview
Sacral neuromodulation, also known as sacral nerve stimulation, is a type of electrical stimulation. Sacral neuromodulation system is an implanted system that can help improve the functioning of the bladder by sending electrical signals to the nerves, which control bladder activities.
This report provides a deep insight into the global Sacral Neuromodulation System market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Sacral Neuromodulation System Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Sacral Neuromodulation System market in any manner.
Global Sacral Neuromodulation System Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Medtronic, Inc. (US)
Boston Scientific Corporation (US)
St. Jude Medical, Inc. (US)
Synapse Biomedical, Inc. (US)
Nevro Corporation (US)
Neurosigma, Inc. (US)
Neuropace, Inc. (US)
Neuronetics, Inc. (US)
Cyberonics, Inc. (US)
BioControl Medical (Israel)
Market Segmentation (by Type)
Internal Neuromodulation System
External Neuromodulation System
Market Segmentation (by Application)
Spinal Cord Stimulation
Deep Brain Stimulation
Sacral Nerve Stimulation
Vagus Nerve Stimulation
Geographic Segmentation
